BioStockInfo · catalyst calendar
/
← Catalyst calendar

NBTX biotech catalysts & pipeline

NANOBIOTIX SA · Data as of 2026-09-08

Upcoming catalysts

NBTXR3 — Full data

H2 2026

While Part 1 data for CONVERGE provides promising signals, the MD Anderson NSCLC reirradiation trial—which evaluates one of the most difficult-to-treat and resistant NSCLC populations—has also shown positive efficacy signals that could suggest a larger potential impact of JNJ-1900 (NBTXR3) in earlier lines of treatment, with final 24-patient data expected in the second half of 2026.
Source filing

NBTXR3 — Interim data

in 1H2027

Following the transfer and Nanobiotix analysis of the latest information, Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the requisite number of events have been observed and the last patient has been recruited, in 1H2027.
Source filing

Explore the free biotech catalyst calendar